Pharmalyst had previously posted re oral factor Xa inhibitors. Pharmalyst had promised readers parts 2 & 3 outlining unmet needs in this market and the prospects for Rivaroxaban and Apixaban - two molecules in this class. While googling this topic, Pharmalyst found this presentation from Dr. C Michael Gibson of Harvard U which pretty much covers the above. Selected excerpts are here:...These have been removed as the clinicaltrialresults.org site does not allow posting of the slides/excerpts. However readers can follow the link above to view the presentation.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment